Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial

Published:2014-11-22 Issue:4 Volume:32 Page:531-541
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:Diabet. Med.

Author:

Bailey C. J.¹,Morales Villegas E. C.²,Woo V.³,Tang W.⁴,Ptaszynska A.⁵,List J. F.⁵

Affiliation:

1. Life and Health Sciences; Aston University; Birmingham UK

2. Aguascalientes Cardiometabolic Research Center; Aguascalientes Mexico

3. University of Manitoba; Section of Endocrinology and Metabolism; Winnipeg Canada

4. Bristol-Myers Squibb; Hopewell NJ USA

5. Bristol-Myers Squibb; Princeton NJ USA

Funder

AstraZeneca and Bristol-Myers Squibb

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dme.12624/fullpdf

Reference34 articles.

1. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study;Stratton;BMJ,2000

2. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012

3. Active sugar transport in health and disease;Wright;J Intern Med,2007

4. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes;Rahmoune;Diabetes,2005

5. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats;Han;Diabetes,2008

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

2. First-time Usage of SGLT2 Inhibitors in Patients with Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety;2024-08-06

3. SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials;Journal of Cardiovascular Electrophysiology;2024-06-28

4. Transporter Proteins as Therapeutic Drug Targets—With a Focus on SGLT2 Inhibitors;International Journal of Molecular Sciences;2024-06-25

5. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3